Findings

What do systematic reviews say?

61 questions · 61 findings · 14 reviews · Neuromuscular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 21 · 34.4%GRADE not reported 2 · 3.3%Very low 18 · 29.5%Low 11 · 18%Moderate 9 · 14.8%High 0 · 0%

Ascorbic acid vs placebo

Health‐related quality of life (mental) · people with fatigue in peripheral neuropathy

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 123 participants
Moderate

Amantadine vs placebo

Fatigue · people with fatigue in Guillain‐Barré syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Amantadine vs placebo

Change in activity limitations · people with fatigue in Guillain‐Barré syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Amantadine vs placebo

Participation · people with fatigue in Guillain‐Barré syndrome

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
74 participants
Low

Amantadine vs placebo

Health related quality of life after 12 or more weeks or more after commencement of intervention (not reported) · people with fatigue in Guillain‐Barré syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Ascorbic acid vs placebo

Fatigue · people with fatigue in peripheral neuropathy

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 404 participants
Moderate

Endoscopic vs open or mini‐open carpal tunnel release

Overall improvement at more than 3 months Participants' subjective evaluation · carpal tunnel syndrome

Endoscopic showed no clear difference in overall improvement at more than 3 months Participants' subjective… compared with open or mini‐open carpal tunnel release (low certainty).

1 finding from 1 review

Endoscopic release for carpal tunnel syndrome 2014 · Cochrane Headline outcomes only
RR 1.04 [0.95, 1.14]
4 studies · 317 participants
Low

Endoscopic vs open or mini‐open carpal tunnel release

Symptom Severity Scale (Levine) at more than 3 months Participants' self assessment questionnaire. Scale from: 1 to 5. · carpal tunnel syndrome

1 finding from 1 review

Endoscopic release for carpal tunnel syndrome 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 273 participants
Low

Endoscopic vs open or mini‐open carpal tunnel release

Function Status Scale (Levine) at more than 3 months Participants' self assessment questionnaire. Scale from: 1 to 5. · carpal tunnel syndrome

1 finding from 1 review

Endoscopic release for carpal tunnel syndrome 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 273 participants
Low

Endoscopic vs open or mini‐open carpal tunnel release

Grip strength ‐ Vitamin D · carpal tunnel syndrome

1 finding from 1 review

Endoscopic release for carpal tunnel syndrome 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 56 participants
Low

Short‐term (1 week) change in isolated movement, objective and subjective measures of speech production SARA. Scale from: 0 to 6. Higher scores indicate more severe speech disorder. · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 13 participants
Very low

Riluzole vs placebo

Short‐term (within 1 month) change in isolated movement, objective and subjective measures of speech production Cooper 2008 reported 3 speech measures: ICARS speech subscale. Scale from: 0 to 8. Higher scores indicate greater clinical severity Syl... · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 38 participants
Low

Physiotherapy and occupational therapy vs placebo

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 42 participants
Very low

Betamethasone vs placebo

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
13 participants
Moderate

Neurodynamic mobilisation vs no treatment

CTS symptoms (Boston CTS questionnaire) ‐ long‐term improvement: > 3 monthsScale: 1 to 5, higher is worse · People with carpal tunnel syndrome on a waiting list for carpal tunnel release

1 finding from 1 review

Exercise and mobilisation interventions for carpal tunnel syndrome 2012 · Cochrane Headline outcomes only
no estimate extracted
1 study · 14 participants
Very low

Neurodynamic mobilisation vs no treatment

Long‐term improvement in functional ability or health‐related quality of life (more than three months) · People with carpal tunnel syndrome on a waiting list for carpal tunnel release

1 finding from 1 review

Exercise and mobilisation interventions for carpal tunnel syndrome 2012 · Cochrane Headline outcomes only
no estimate extracted
1 study · 14 participants
Very low

Eplerenone (25 mg daily) vs placebo

Change in cardiac function: change (decline) from baseline in left ventricular strain · boys with DMD and left ventricular ejection fraction 45% or more

1 finding from 1 review

Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X‐linked… 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 42 participants
Very low

Eplerenone (25 mg daily) vs placebo

Change in Ejection fraction (%) · boys with DMD and left ventricular ejection fraction 45% or more

1 finding from 1 review

Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X‐linked… 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 42 participants
Very low

Eplerenone (25 mg daily) vs placebo

Size of metabolically abnormal areas of myocardium · boys with DMD and left ventricular ejection fraction 45% or more

1 finding from 1 review

Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X‐linked… 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 42 participants
Low

Eplerenone (25 mg daily) vs placebo

Improvements in quality of life measures · boys with DMD and left ventricular ejection fraction 45% or more

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X‐linked… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found